Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals announces participation in the 2022 Virtual JMP Securities Hematology and Oncology Summit on December 6 at 2:40 p.m. ET. The company will highlight TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor, aimed at treating chronic myeloid leukemia (CML). CEO Sen Sundaram emphasized TERN-701’s potential to improve patient outcomes, showcasing its efficacy and tolerability over existing therapies. A live audio webcast will be accessible on Terns' investor relations page, with on-demand availability for 30 days post-event.

Terns Pharmaceuticals plans to initiate U.S. clinical trials for TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), in the second half of 2023. Positive Phase 1 data for TERN-501 (THR-β agonist) in NASH was presented, with top-line results from the Phase 2a DUET trial expected later in 2023. Cash reserves of $187 million are projected to fund operations into 2025, supporting three key clinical program readouts. The company anticipates significant milestones ahead, including clinical advancements for TERN-601 targeting obesity.

Terns Pharmaceuticals presented positive Phase 1 results for TERN-501, a THR-β agonist targeting NASH, at The Liver Meeting. Among 24 participants, TERN-501 demonstrated a dose-dependent increase in sex hormone binding globulin (SHBG), with 100% of those on the highest dose showing significant increases. The ongoing Phase 2a DUET trial will evaluate TERN-501's safety and efficacy, both alone and in combination with TERN-101, with top-line data expected in late 2023.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced plans to present two abstracts at the AASLD The Liver Meeting® from November 4-8, 2022. The presentations will focus on TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, both under investigation for treating non-alcoholic steatohepatitis (NASH). The first abstract highlights TERN-501’s effects on sex hormone binding globulin and lipid levels, while the second discusses an ongoing Phase 2a study of TERN-501 and TERN-101 in NASH patients, with top-line results expected in late 2023.

Terns Pharmaceuticals, based in Foster City, is set to present at the H. C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 a.m. ET. The company focuses on developing small-molecule therapies targeting serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). A live webcast of the presentation will be available on their investor relations page, with a replay accessible for 30 days. Terns' pipeline includes multiple clinical-stage programs aimed at serious health conditions.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: TERN), is set to present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:00 p.m. ET. The company focuses on developing small-molecule therapies for serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). Interested investors can access a live audio webcast of the presentation on Terns' investor relations page, with a replay available for 30 days post-event.

Terns Pharmaceuticals has announced an underwritten public offering of 12,250,000 shares at $2.42 each and pre-funded warrants for 14,630,000 additional shares at $2.4199 each, targeting gross proceeds of approximately $65 million. The offering, which is set to close on August 16, 2022, is oversubscribed and led by new investors, including Fairmount and Venrock Healthcare Capital Partners. Proceeds will fund clinical studies in chronic myeloid leukemia, obesity, and ongoing trials for NASH, alongside general corporate purposes.

Terns Pharmaceuticals reported progress on its clinical trials for three drug candidates targeting chronic myeloid leukemia, obesity, and NASH. TERN-701 is advancing to a Phase 1 trial in China, while TERN-601 is on schedule to begin a Phase 1 obesity trial in 2023. The company initiated dosing for TERN-501 in a Phase 2a trial for NASH, with results expected in the second half of 2023. As of June 30, 2022, Terns has $140 million in cash, providing a financial runway into 2025, despite a net loss of $13.9 million for the quarter.

On July 27, 2022, Terns Pharmaceuticals (Nasdaq: TERN) appointed Dr. Radhika Tripuraneni to its Board of Directors. Dr. Tripuraneni, the Chief Development Officer at Prothena Corporation, boasts over 15 years of drug development experience. She aims to leverage her expertise to guide Terns in advancing its pipeline of small-molecule candidates targeting serious diseases such as NASH, obesity, and cancer. CEO Sen Sundaram emphasized her valuable support in generating meaningful clinical data for these significant unmet needs.